ScreenerHero

MNKDMannKind Corporation

NAS · US · Healthcare · Biotechnology · mannkindcorp.com
4.150USD-5.57%Mkt Cap: 1.33B $P/E: —

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.33B $
Enterprise Value1.69B $
Revenue (TTM)393.63M $
Gross Profit261.01M $
Net Income (TTM)5.86M $
Revenue/Share1.423 USD
Last Price4.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees591
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS56400P7069
Valuation
P/E (Trailing)—
P/E (Forward)33.41
PEG4.39
EV/EBITDA60.16
EV/Revenue4.30
P/S3.46
P/B-25.66
EPS (TTM)-0.15
EPS (Forward)0.13
52W Range
2.23045% of range6.510
52W High6.510 USD
52W Low2.230 USD
Profitability
Gross Margin74.79%
Oper. Margin-0.76%
EBITDA Margin7.15%
Profit Margin1.68%
ROE-11.49%
ROA0.74%
Growth
Revenue Growth42.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.25M $
CapEx (TTM)4.57M $
FCF Margin10.24%
FCF Yield3.02%
Net Debt322.70M $
Net Debt/EBITDA11.47
Balance Sheet
Debt/Equity-7.20
Current Ratio1.72
Quick Ratio1.29
Book Value/Sh-0.1660 USD
Cash/Share0.3460 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2017
Splits
Last Split1:5
Split DateMar 3, 2017
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.969 USD
Upside (mean)+92.0%
Target Range4.750 USD – 13.00 USD
$4.750+92.0% to mean$13.00
# Analysts8
Ownership
Shares Out.321.54M
Float297.53M
Insiders1.47%
Institutions57.29%
Short Interest
Short Ratio5.8d
Short % Float8.79%
Short % Out.8.68%
Shares Short27.90M
Short (prev mo.)26.19M
Technical
SMA 503.999 (+3.8%)
SMA 2004.232 (-1.9%)
Beta1.10
S&P 52W Chg18.16%
Avg Vol (30d)4.56M
Avg Vol (10d)4.16M
Technical Indicators
RSI (14)54.4
MACD0.0307
MACD Signal0.0063
MACD Hist.+0.0244
BB Upper4.276 USD
BB Middle3.963 USD
BB Lower3.649 USD
BB Width15.83%
ATR (14)0.2410 USD
Vol Ratio (20d)0.65x